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Introduction 
Vectors based upon retroviruses remain the system of choice for achieving retention and 
function of therapeutic genes within a desired tissue, especially when targeting mitotic stem 
cell populations. Indeed, the use of gammaretroviral and lentiviral vectors have provided very 
encouraging positive results in clinical trials for a number of different conditions, particularly 
targeting the haematopoietic system for conditions such as severe immune deficiency (see 
Candotti, 2014; Cavazzana, 2014) and leukodystrophies (Cartier et al., 2009; Biffi et al., 2013). 
As part of this strategy, achieving reproducibility and stability of therapeutic gene expression 
remain essential components. This is especially the case in circumstances where no selective 
growth and survival advantage of corrected cells is expected (Antoniou et al., 2013).  
A class of transcriptional regulatory element that has shown great promise at providing both 
reproducible and long-term stable transgene expression from within lentiviral vectors (LVs) is 
the ubiquitous chromatin opening element from the human CBX3-HNRPA2B1 housekeeping 
gene locus (A2UCOE). The prototypical A2UCOE fragment from this locus consists of a 
methylation-free CpG island encompassing the dual divergently transcribed CBX3 and 
HNRPA2B1 promoters and is capable of negating transgene silencing even with integration 
events within centromeric heterochromatin (Antoniou et al., 2003, Williams et al., 2005). These 
properties argue that the A2UCOE possesses a dominant chromatin remodelling or opening 
function, which prevents transgene silencing through blocking the spread of heterochromatin 
and DNA methylation of the promoter driving transgene expression (Antoniou et al., 2003, 
Williams et al., 2005, Lindahl Allen and Antoniou, 2007).  
More recently, the A2UCOE has been demonstrated to be highly efficacious within an LV 
context. The A2UCOE has been shown to provide stable function both in vitro and more 
importantly haematopoietic stem cells (HSCs) and their differentiated progeny in vivo from 
direct expression off the HNRPA2B1 promoter (Zhang et al., 2007 and 2010). In addition, an 
A2UCOE sub-fragment spanning the CBX3 promoter alone has also been shown to provide 
stable expression albeit at much lower levels than that from the HNRPA2B1 promoter (Müller-
Kuller et al., 2015). The A2UCOE can also confer stability of expression on linked, silencing-
prone ubiquitous (Williams et al., 2005; Zhang et al., 2010; Pfaff et al., 2013; Phaltane et al., 
2014) and tissue-specific (Brendel et al., 2012) promoters. Furthermore, A2UCOE-based LVs 
are the first to be shown to provide stability of expression in both embryonic and induced 
pluripotent stem cells and differentiated progeny of all three germ layers (Pfaff et al., 2013; 
Ackermann et al., 2014). The resistance to transcriptional silencing conferred by the A2UCOE 
is at least in part due to its ability to prevent DNA methylation of its own and linked 
heterologous promoters (Zhang et al., 2010; Brendel et al., 2012; Pfaff et al., 2013; Ackermann 
et al., 2014).  
All evaluations to date of A2UCOE-based LV efficacy have been conducted in adult mouse 
model systems (Antoniou et al., 2013). An alternative gene therapy approach is that involving 
direct in vivo LV delivery to the developing fetus. Such prenatal gene therapy has a number 
of distinct advantages, especially when targeting stem cell populations such as HSCs 
including lower vector dose, targeting of rapidly expanding stem cell populations, inducing 
immune tolerance to the therapeutic gene product and ultimately prevention of disease onset 
that would normally occur either before or after birth (Coutelle and Waddington, 2012; Mattar 
et al., 2012; Loukogeorgakis and Flake, 2014). The fetal liver is the major haematopoietic 
organ at this stage of development and therefore the site of HSCs during gestation. Therefore 
therapeutic viral vectors delivered to the murine fetal liver pre-natally via yolk sac-associated 
blood vessels such as the vitelline duct, which joins the yolk sac to the midgut lumen of the 
developing fetus, are able to transduce not only hepatocytes but also HSC before the latter 
migrate to bone marrow. Thus long-term post-natal therapeutic benefit can potentially be 
achieved by the targeting of either or both of these organ systems. 
We recently demonstrated that human fetal liver-derived HSCs are readily transducible with 
A2UCOE, PGK and EF1α promoter-based LVs but with only the A2UCOE construct provided 
stable, long-term expression especially following transplantation into mice (Dighe et al., 2014). 
Here we extend these ex vivo studies by evaluating a series of A2UCOE reporter (eGFP, 
luciferase) gene and human coagulation factor IX (FIX) cDNA LVs following direct pre-natal 
delivery to the murine fetal liver. Our results show stable post-natal vector presence in both 
the liver and haematopoietic system with concomitant persistence of expression 
demonstrating efficient LV transduction of both fetal hepatocytes and HSCs. Most 
encouragingly, the A2UCOE-FIX construct, at a low (0.2) average vector copy number per 
liver cell, was able to provide stable levels of plasma FIXFIX productionwhich would convert 
severe haemophilia B (<1%) to a mild phenotype (≈20%). . Thus our results provide proof-of-
principle for low dose pre-natal A2UCOE-based LV delivery to the liver as a therapeutic option 
for Haemophilia B and potentially other metabolic conditions. 
 
Materials and Methods 
Lentiviral vector constructs 
The lentiviral vector (LV) containing an enhanced green fluorescent protein reporter gene 
under control of the 2.5kb A2UCOE was in a standard HIV-1 based backbone with the U3 
region within the 3’LTR deleted to render the construct self-inactivating (Zhang et al., 2007). 
The eGFP gene was followed by the woodchuck hepatitis virus post-transcriptional regulatory 
element (WPRE) to give the construct A2UCOE-eGFP-WPRE. Expression is driven off the 
HNRPA2B1 promoter of the A2UCOE (Antoniou et al., 2003; Zhang et al., 2007). The LV 
containing an A2UCOE-luciferase-WPRE cassette was kindly provided by Natalie Ward and 
Adrian Thrasher (Institute of Child Health, University College London, UK) and is as the 
A2UCOE-eGFP-WPRE vector but with the eGFP gene replaced with a 1.6kb luciferase cDNA 
coding sequence. The A2UCOE-FIX-WPRE was within a pRRLSIN18 LV backbone (Follenzi 
et al., 2002) and consisted of a 2.2kb A2UCOE (Antoniou et al., 2003) driving expression of 
human FIX cDNA followed again by the WPRE. The SFFV-FIX-WPRE vector is as previously 
described and consists of the FIX cDNA transcribed from the spleen focus forming virus 
(SFFV) promoter-enhancer (Waddington et al., 2004).      
 
Lentiviral vector generation 
Stocks of HEK293T cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 4500mg/l L-anany-L-glutamine, 4.5µg/l glucose, 10µg/ml penicillin and 
streptomycin and 10% of fetal bovine serum (GE Healthcare Ltd, Chalfont St Giles, 
Buckinghamshire, UK). Cells were cultured at 37℃ in a 5% CO2 atmosphere within a 
NuaireDH Autoflow Air Jacketed CO2 incubator (Plymouth, Minnesota, USA). Lentiviral vector 
stocks were produced using standard methods by transient transfection of HEK293T cells as 
before (Talbot et al., 2010). Briefly, cells were grown to 70-80% confluence in 15cm diameter 
Petri-dishes and transfected with a mixture of 50µg of transfer vector, 17µg of envelope 
(pMDG) and 32µg of packaging Gag/Pol (pCMVdR8.74) plasmids using polythylenimine (PEI, 
Sigma-Aldrich). Culture medium was replaced with 13ml fresh complete DMEM culture 
medium the next day and virus-containing culture supernatant harvested at 72h and 96h post-
transfection. Virus was concentrated by centrifugation and resultant viral pellets resuspended 
in DMEM medium and stored in aliquots at -80℃. 
 
Lentiviral vector titration 
The titre of each concentrated LV stock was performed by transducing HEK293T cells and 
assaying for provirus at 3 days post-transduction by flow cytometry for eGFP reporter gene-
based vectors and by quantitative polymerase chain reaction (qPCR) for the FIX-containing 
LVs.  
 
Flow cytometry 
The percentage of eGFP positive cells was assessed by using a Becton Dickinson FACS 
Calibur (BD Biosciences; Franklin Lakes, New Jersey, USA) and CellQuestTM software 
(version 5.2.1; BD Biosciences, La Jolla, California, USA). 
 
Quantitative PCR (qPCR) 
Determination of vector copy number per cell was by qPCR analysis of DNA from murine 
tissues or cultured cell DNA. Total genomic DNA from mouse tissues or 5-10 x106 tissue 
culture cells was isolated using the Promega Wizard® Genomic DNA purification kit (Promega 
UK, Southampton, UK), which was used in accordance with the manufacturer’s instructions. 
Extracted DNA was diluted to a working concentration of 2-20ng/µl. The qPCR reactions were 
set-up in 96-well reaction plates (MicrpAmpTM Optical; Applied Biosystems, Forster City, 
California, USA) and reactions run in a 7900HT Fast Real Time PCR System (Applied 
Biosystems) instrument using Bushman’s late reverse transcriptase (LRT) primer/probe set 
(Bushman et al., 2001). The LRT primers amplify the region of the HIV vector backbone 
between the right 5’ LTR sequence and the 5’ end of the gag gene such that only integrated 
DNA or proviral forms that have completed the two template switches of reverse transcription 
to double stranded DNA are detected. The sequences of Bushman’s LRT primer sequences 
are as follows: LRT forward: 5’ TGTGTGCCCGTCTGTTGTGT  3’; LRT reverse: 5’ 
GAGTCCTGCGTCGAGAGAGC  3’; LRT probe: 5’ – (FAM) – 
CAGTGGCGCCCGAACAGGGA – (TAMRA)  3’. A clonal cell line with an independently 
determined viral copy number of one was used as a standard reference. 
The endogenous human (GAPDH) or mouse (Gapdh) glyceraldehde-3-phosphate 
dehydrogenase gene was used to determine absolute numbers of genomes present in each 
qPCR reaction using the following primer/probe set to amplify the 5’ end of exon V: GAPDH 
forward: 5’ ACCACAGTCCATGCCATCACT 3’; Gapdh (mouse) reverse: 5’ 
GGCCATCACGCCACAGCTT 3’; GAPDH probe: 5’ – (FAM) – 
CCACCCAGAAGACTGTGGATGGCC – (TAMRA) 3’. 
The qPCR reactions employed the TaqMan Master Mix (PrimerDesign Ltd, Southampton, 
UK). The GAPDH and LRT reactions of each sample were run in duplicate and in parallel with 
standard reference samples. Quantification was conducted with Sequence Detection Systems 
software (SDS version 2.2.2 Applied Biosystems, 2004) by reference to standard curves 
created by known copy number standard references. Viral copy number per genome was 
calculated by using Microsoft® Excel. 
 
Protein extraction 
Whole organs from mouse tissues were homogenised in 2ml of phosphate buffered saline 
(PBS), from which 500µl was taken for protein extraction in 500µl protein extraction solution 
(PBS containing 0.05% Tween20® and 0.05% Triton X-100 [(v/v; Sigma-Aldrich Company Ltd, 
Poole, Dorset, UK)]. Tissue homogenates were centrifuged for 5 minutes at 13,000 rpm, 
supernatant collected and stored at -20℃ until use for protein analysis. 
 
FIXFIX enzyme linked immunosorbent assay (ELISA) 
Samples for analysis of FIX concentration were collected from mouse tissues (total protein), 
serum or cell culture supernatant. FIX ELISA was conducted using the Matched-Pair Antibody 
Set antigen kit (Affinity BiologicalsTM Inc., Ancaster, Ontario, Canada) in accordance with the 
manufacturer’s instructions. 
 
In vivo studies 
Work in vivo using wild type MF1 mice was conducted under United Kingdom Home Office 
regulations and was compliant with the guidelines of the Imperial College London and 
University College London ethical review committees. 
Pre-natal delivery of LVs was by injection of a 20µl volume containing >1 x 109 viral particles 
per ml into each fetus via the yolk sac-associated vitelline vessel (Waddington et al., 2004) at 
either day 14 or 16 of gestation. The injected fetus was marked in utero, for post-partum 
identification, by injection of colloidal carbon into the flank (>2µl). A particular foot was tattooed 
again for identification after birth. Injected mice were bled via the tail vein every month post-
injection and culled after 5-8 months for blood and organ analysis. 
 
In vivo bioluminescent imaging 
Mice were anesthetised with isoflurane using Boyle’s apparatus, and injected intraperitoneally 
with 300μL of 15mg/mL D‐luciferin salt. Mice were left for 5 minutes exactly and then imaged 
for bioluminescence by the IVIS Imaging 50 Series system (Caliper Life Sciences Ltd, 
Runcorn, UK). After acquiring a gray‐scale photograph a bioluminescence image was 
obtained with a 12‐cm field of view, a binning (resolution) factor of 1 or 8, and a 1/f stop and 
open filter. Signal intensities were calculated with Living Image 2.50 software (Xenogen) and 
expressed as photons per second per centimetre squared per steradian 
(photons/second/cm2/sr).  
 
Results 
A2UCOE-based lentiviral vectors provide stable expression following pre-natal delivery to the 
liver  
In order to establish proof-of-principle of pre-natal delivery to the fetal liver, we initially 
employed two lentiviral vector reporter gene constructs namely A2UCOE-eGFP (Figure 1A) 
and A2UCOE-lucifersase (Figure 2A). 
Fetuses of wild-type MF1 strain mice (n=9) were injected with 20µl of the A2UCOE-eGFP 
vector at a concentration of 1x109 vp/ml via the yolk sac-associated vitelline duct at day 14 of 
gestation. All the mice were sacrificed at 150 days after birth for further analysis. Livers were 
isolated post-mortem and analysed by fluorescence microscope to detect any eGFP positive 
cells (Figure 1B). Bone marrow (BM) as well as spleen, lung and heart were also removed for 
determination of vector copy number (VCN) per genome using quantitative PCR (qPCR) 
(Figure 1C). All pre-natally injected animals showed normal tissue morphology compared to 
uninjected controls (data not shown).   
Figure 1B shows three representative liver samples from injected fetuses observed by 
fluorescence microscopy. All three treated mice (UG-1, UG-2 and UG-3) showed a similar 
expression pattern of eGFP, while no eGFP positive cells were seen in the uninjected negative 
control mouse. The widespread and uniform punctuate fluorescent pattern suggested efficient 
pre-natal transduction of hepatocytes and clonal expansion of transduced cells.   
Analysis of average VCN per genome revealed vector presence in liver, spleen and BM with 
values of 2.22, 0.55 and 0.95 respectively. Vector was undetectable in lung and heart tissues. 
As the fetal liver is also the site of haematopoiesis, these data demonstrate that the A2UCOE-
eGFP vector had also transduced haematopoietic stem cells (HSCs) with subsequent natural 
migration to BM post-natally. The higher VCN detected in the liver also suggests that 
hepatocytes are more readily transducible than fetal HSCs.  
In order to allow monitoring of A2UCOE-based lentiviral vector expression within the liver over 
time in live animals, we next conducted a series of experiments with the A2UCOE-Luciferase 
construct (A2UCOE-Luc; Figure 2A). 
As before fetuses of wild-type MF1 strain mice (n=3) received 20µl of the vector preparation 
at a concentration of 1.32 x109 vp/ml via the vitelline duct. Bioluminescence imaging was 
undertaken with live animals at 1 and 12 months after birth using the Xenogen system after 
intraperitoneal injection of luciferin (Figure 2B). All three animals injected with the A2UCOE-
Luc vector showed strong bioluminescence in the area corresponding to the liver at one month 
of age (Figure 2B, upper panel) and which was maintained to the termination of the experiment 
at 12 months (Figure 2B, lower panel). Quantification of luminescence imaging of the 
luciferase transgene expression in liver gave an average radiance of 6.25x106 and 3.59x106 
p/s/cm2/sr for the three treated mice at 1 and 12 months respectively (Figure 2C). Thus a 
decrease of luciferase transgene expression of 1.7-fold was observed between 1 and 12 
months. Treated and control mice were sacrificed at 1 year of age for further analysis. Again 
BM, spleen, lung and heart as well as liver were removed for quantification of average VCN 
per genome. The results (Figure 2D) show an average VCN of 2.36, 0.8 and 2.49 for liver, 
spleen and BM respectively. Thus in contrast to the data obtained with the A2UCOE-eGFP 
vector (Figure 1C), the VCN in BM matched that of the liver. No vector was detected within 
either lung or heart tissues.  
The average bioluminescence radiance per VCN of hepatocyte cells for the three treated mice 
was 1.41x106 p/s/cm2/sr (Figure 2E). Protein extracts from BM or spleen were used to conduct 
luciferase assays and showed an average luciferase expression level per VCN for spleen and 
BM of 6.15x103 and 2.23x103 RLU/ng protein/VCN respectively (Figure 2F). 
In summary, these results with the A2UCOE-eGFP and A2UCOE-Luc constructs show that 
pre-natal injection via the vitelline duct successfully and efficiently delivers lentiviral vectors to 
the fetal liver transducing both hepatocytes and HSCs.  
 
Stable, Haemophilia B curative levels of human FIX production from an A2UCOE-based vector    
The encouraging proof-of-principle data from the pre-natal delivery of A2UCOE-eGFP and 
A2UCOE-Luc LVs to the fetal liver (Figures 1 and 2), led us to investigate whether a similar 
approach could be employed with a therapeutic vector harbouring an A2UCOE-human factor 
9 (A2UCOE-FIX) transgene (Figure 3A). A previously employed LV containing an FIX cDNA 
under control of the spleen focus forming virus promoter/enhancer (SFFV-FIX; Figure 3A), 
acted as a reference construct (Waddington et. al., 2004). The titres of the SFFV-FIX and 
A2UCOE-FIX vectors were quantified by qPCR at three days post-transduction of HEK293T 
or K562 cells and gave values of 1x1010 and 8x108 vp / ml respectively.  
For the SFFV-FIX group, fetuses of wild-type MF1 strain mice were injected with 20µl of vector 
via the vitelline duct at day 16 of gestation (n=6; SF1-SF-6). In the case of the A2UCOE-FIX, 
animals were injected at day 14 of gestation giving rise to three out of nine (UF1-UF3) being 
born for investigation. 
Peripheral blood was collected at periodic intervals to quantify the plasma FIX concentration 
by ELISA at post-natal day 21, 60 and 150 for the SFFV-FIX group and 90, 150 and 210 days 
after birth for the A2UCOE-FIX animals. All animals for both vector groups were sacrificed at 
the final blood sample collection time point for molecular analysis of peripheral blood, plasma, 
BM and liver tissues. 
The results from the SFFV-FIX injected animals showed that the concentration of plasma FIX 
rose significantly by 3-fold from 1 to 3.55µg/mL between post-natal days 21 and 150 (Figure 
3B, top panels). For the A2UCOE-FIX group, the average concentration of plasma FIX was 
1.74µg/mL (+0.36), 1.96µg/mL (+0.17) and 1.53µg/mL (+0.23) at 90, 150 and 210 days after 
birth respectively. Thus transgene expression from the A2UCOE-FIX vector was stable and 
consistent throughout the 210 day period of the study (Figure 3B, lower panels). Of note is 
that both vector systems provided well in excess of the minimum 5% of normal plasma FIX 
values (250ng/ml) required for therapeutic benefit. Indeed, the levels obtained are above the 
threshold of 20% normal values of FIX (1.25µg/ml) recognized to be curative for Haemophilia 
B.        
The animals of SFFV-FIX and A2UCOE-FIX vector groups were sacrificed at post-natal days 
150 and 210 respectively for molecular analysis of the peripheral (white) blood cell (WBC) 
fraction, plasma, BM and liver tissues. Genomic DNA was analysed to determine average 
VCN per genome analysis by qPCR. The results show either a very low 0.12 (+0.13) and 
undetectable VCN per genome of the SFFV-FIX vector to be present in WBC and BM cells 
respectively (Figure 4A, top panel). For A2UCOE-FIX transduced group, there were no 
detectable vector sequences in either WBC or BM cells at the time of sacrifice. However, 
analysis of liver samples showed an average VCN per genome of 0.27 (+0.09) for the SFFV-
FIX group (Figure 4A) and 0.2 (+0.02) for the A2UCOE-FIX vector injected mice (Figure 4B).  
The results we obtained with the A2UCOE reporter gene constructs (Figures 1 and 2) suggest 
that in all likelihood the primary source of circulating FIX was the liver. Therefore we next 
measured the FIX concentration in whole livers from both SFFV-FIX and A2UCOE-FIX mouse 
groups. Following homogenization of whole organs in 2ml of PBS and protein extraction, the 
amount of FIX was determined by ELISA. The results (Figure 4C) show that FIX production 
was on average 7.32 (+2.24) ng/µg protein/VCN in SFFV-FIX injected animals and 32.93 
(+4.56) ng/µg protein/VCN for the A2UCOE-FIX group. Thus in conclusion, circulating levels 
of FIX were emanating from the liver and production from the A2UCOE-FIX cassette was 
approximately 4.5 fold higher per average VCN per genome than that obtained from the SFFV-
FIX construct.   
 
Discussion 
Although pre-natal viral gene therapy has attracted significant interest it has been hampered 
in terms of translation to the clinic by inefficient delivery, especially at acceptable doses and 
safety concerns, particularly inadvertent transduction of reproductive germ cells (Coutelle and 
Waddington, 2012; Mattar et al., 2012; Loukogeorgakis and Flake, 2014). Here we show that 
A2UCOE-based LVs can efficiently transduce the hepatocytes, and to a lesser degree the 
HSCs, of the murine fetal liver in vivo by delivery via the yolk sac-associated vitelline duct. 
The A2UCOE-based constructs were designed to drive expression of both reporter and FIX 
genes directly from the innate HNRPA2B1 promoter, which as in the case of targeting adult 
HSCs (Zhang et al., 2007), provided reproducible and stable transgene expression post-
natally. Most encouragingly, we obtained stable Haemophilia B curative levels of FIX (at 20% 
of normal) in the plasma of injected mice at a low (0.18) average vector copy number per cell 
(Figures 3 and 4). 
 
Although our results with the A2UCOE-eGFP and A2UCOE-Luc reporter gene constructs 
indicated that delivery of vector via the vitelline duct transduced both hepatocytes and HSCs 
(Figures 1 and 2), our analysis of A2UCOE-FIX and SFFV-FIX LV distribution between liver, 
peripheral blood and bone marrow post-natally detected vector only in liver, especially in the 
case of the animals administered with the with A2UCOE-FIX construct (Figures 4A and 4B). 
Thus we can conclude that the levels of plasma FIX seen in animals post-natally was 
essentially arising from secretion from the liver, as previously described   (Waddington et al., 
2004). In addition, these results suggest that a relatively low amount of LV can be employed 
in pre-natal gene therapy to achieve high transduction efficiency of fetal hepatocytes to give a 
therapeutic level expression. Our data also implies that perhaps larger amounts of LV will be 
required to transduce HSCs in the murine fetal liver. 
 
The SFFV-FIX LV construct used as a reference in the study presented here, has previously 
been shown to provide Haemophila B curative plasma levels of FIX in mice following direct 
pre-natal delivery of this viral vector (Waddington et al., 2004) and ex vivo transplanted HSCs 
following vector transduction (Bigger et al., 2006), albeit in the latter case at high average 
vector copy number per cell (greater than 10 in the majority of cell compartments analysed). 
However, given the demonstrated insertional mutagenesis potential of the SFFV element via 
its potent enhancer component (Stein et al., 2010), this promoter is no longer seen as viable 
option for inclusion within therapeutic LV cassettes. In our study the efficiency of expression 
from A2UCOE-FIX was comparable to that from the SFFV-FIX vector (Figures 3B and 3C) but 
at a lower average vector copy number per cell (Figures 4A and 4B). In addition, production 
of FIX per vector copy in liver was 4.5-fold higher from A2UCOE-FIX than SFFV-FIX (Figure 
4C). Furthermore, A2UCOE efficacy of function at low LV copy number per cell coupled with 
a lack of classical enhancer function (Zhang et al., 2007) and engineering to eliminate aberrant 
splicing (Knight et al, 2012), combine to produce a low risk of insertional mutagenesis and 
thus, in principle, a high safety profile.  
 
The results with the A2UCOE-hF.IX vector show that the A2UCOE was able to give stable 
and consistent transgene expression throughout a long period. A constant level of hF.IX 
production was produced over 7 months. The qPCR results of peripheral blood, bone marrow 
and liver cells showed that viral vectors were all integrated in hepatocytes rather than in HSCs 
as originally expected. The hF.IX ELISA of liver cells proved that hF.IX proteins were 
generated and secreted from the liver into circulation. The A2UCOE expression cassette was 
most potent giving high hF.IX production per viral vector copy (32.93µg/VCN) into the 
circulation. Our data strongly suggest that therapeutic levels can be reached to cure 
Haemophilia B with low viral vector copy, thus, efficacy being achieved with a high safety 
profile. In contrast, low A2UCOE-hF.IX vector copy per hepatocyte cells [0.19 (+0.02)] was 
sufficient to give a therapeutic level of hF.IX production. Therefore, the efficacy and safety 
concerns in gene therapy are met with this UCOE-based vector system. 
 
In summary, our results suggest that an in utero, pre-natal gene therapy approach can be 
used to efficiently target fetal liver at low A2UCOE-based LV doses of modest titre (minimum 
of 5x108 vp/ml) and allow high, therapeutic transgene expressed at low average vector copy 
number per cell post-natally. Thus the approach we present here offers a viable alternative to 
high dose adeno-associated viral vector delivery to the liver for the treatment of Haemophilia 
B (High et al., 2014; Lheriteau et al., 2015) and other conditions that require targeting 
therapeutic gene deliver to this organ.   
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